Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Newly built Indian Red Cross Society’s Dr. Cyrus Poonawalla School for Hearing Impaired was unveiled…
Dr. Cyrus S. Poonawalla, Chairman, Serum Institute of India (SII), part of Cyrus Poonawalla group inaugurated the new building
Alembic Pharmaceuticals gains USFDA final approval for Carbamazepine Extended-Release Tablets
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug and also for treating pain associated with…
World Hepatitis Day 2025: Renewed global push urgent need amid rising mortality: GlobalData
GlobalData epidemiologists forecast the total prevalent cases of chronic hepatitis B (CHB) in the 7MM* to reach nearly 4 million…
ICT Mumbai, ITRI sign EOI to catalyse ₹30 cr for construction of Mumbai Biocluster building
The Mumbai Biocluster is a response to bridging the “valley of death” between early-stage discovery and scalable clinical and…
Why India’s B.Pharm graduates need a standardised National Exit Exam
Dr Akram Ahmad, CEO & Founder, Academically Global, says that while India leads in pharma manufacturing and exports,…
Exclusive interview with Dilip Singh Rathod, President India Business, JB Pharma
In this interview, Dilip Singh Rathod, President: India Business, JB Pharma, offers insights into the company's India growth…
Diagnosed prevalent cases of HER2- breast cancer across 8MM set to reach 4.12 mn in 2034
GlobalData’s latest report, reveals that the increase is partly attributed to higher survival rates of HER2- breast cancer…
Pfizer completes licensing agreement with 3SBio
The agreement allows Pfizer to manufacture and commercialise 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF…
India overtakes Iran in clinical trial initiations outside North America and Europe in Q2 2025
GlobalData’s latest report reveals that Iran’s clinical trials have been affected, with 348 trials initiated in Q2, compared to…
Baxdrostat met primary, secondary endpoints in BaxHTN Phase III trial in patients with…
Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor that targets the hormone driving…